

H1500.H15T	Lot No. 611
Cryopreserved Human Hepatocytes	
Donor Information	
Demographics	Serology
Gender: Female	CMV: (+)
Age: 25 Years	HIV: (-)
Race: Caucasian	HBV: (-)
Cause of Death: Cerebrovascular Accident	HCV: (-)

Assured Minimum Yield: 4.0×10^6 per vial

Viability: 91.3%

(Yield and viability are based on experiments performed at XenoTech using XenoTech's thawing protocol and K2000 Hepatocyte Isolation Kit.)

Transporter ¹	Marker substrate uptake (pmol/million cells/min) ^{2§}	
OATP	Estrone-3-sulfate	36 ± 20
NTCP	Taurocholic Acid	4.7 ± 2.2
OCT1	1-Methyl-4-phenylpyridinium Iodine	20 ± 1

Enzyme	Marker substrate reaction (pmol/million cells/min)	
CYP2D6	Dextromethorphan <i>O</i> -demethylation	42.5
CYP2E1	Chlorzoxazone 6-hydroxylation	136
CYP3A4/5	Testosterone 6β-hydroxylation	36.8
UGT	Glucuronidation of 4-Methylumbelliferone	321

¹ OATP (Organic Anion Transporting Polypeptide), NTCP (Sodium Taurocholate Co-transporting Polypeptide), OCT1 (Organic Cation Transporter)

² Data reflect mean and standard deviation from three separate assays performed on three separate days.

[§] Characterization based on methods described in: Halifax D and Houston JB (2006) Uptake and intracellular binding of lipophilic amine drugs by isolated rat hepatocytes and implications for prediction of in vivo metabolic clearance. Drug Metabolism and Disposition 34:1829-1836.

CAUTION: These hepatocyte samples are from donors who tested negative for HIV and hepatitis. However, we recommend that these samples be considered as potential biohazards and that universal precautions be used when working with human derived products.

Store vials in liquid nitrogen, vapor phase.



Data sheet prepared 4/21/09